Generic and Brand Antiseizure Medicines

Generic antiseizure medicines are approved to provide the same active drug and clinically comparable exposure as the reference brand. For most people, approved generics can be used safely—but switching policy is not identical for every medicine, person or country.

What does “generic” mean?

A generic medicine contains the same active ingredient as the reference product and must meet regulatory standards for quality and bioequivalence.

Its colour, shape, packaging and inactive ingredients may differ.

What is bioequivalence?

Bioequivalence studies compare measures such as total drug exposure and peak concentration.

Regulators require the generic product to fall within specified statistical limits relative to the reference product.

The common “80% to 125%” misunderstanding

The regulatory interval does not mean that a generic tablet may contain only 80% of the stated drug or 125% of it.

It refers to confidence intervals around pharmacokinetic comparisons, not tablet potency.

What does the epilepsy evidence show?

Randomised studies and systematic reviews have generally not shown poorer seizure control with approved generic antiseizure medicines compared with brand-name products.

A European re-appraisal of 117 generic products found very narrow exposure differences for most modern antiseizure medicines studied.

Why do some people report problems after switching?

Possible explanations include true pharmacokinetic variation, altered adherence because tablets look different, anxiety around the switch, dispensing errors, changes in release formulation or unrelated fluctuation in seizure frequency.

Not all health systems regulate generics in the same way

Strong regulatory agencies require formal evidence of bioequivalence and manufacturing quality.

In settings with weaker regulatory oversight, product quality and consistency may be more variable.

An ILAE global survey found substantial international differences in confidence, regulatory control and availability.

Immediate-release and modified-release products

Switching between different extended-release or controlled-release formulations deserves additional care because release characteristics matter as well as the active ingredient.

Narrow therapeutic index

Some medicines have a relatively narrow margin between too little drug and excessive exposure.

Regulators may use tighter bioequivalence requirements for these products.

Country-specific rules differ

Some countries allow automatic pharmacy substitution, while others restrict substitution for particular antiseizure medicines.

United Kingdom: current NHS/MHRA-linked guidance separates antiseizure medicines into categories. Carbamazepine, phenobarbital, phenytoin and primidone generally require continuity of a specific manufacturer’s product; for several other medicines, continuity is decided individually.

Tablet appearance matters

A change in colour, shape or packaging can cause confusion, particularly for people taking several medicines or with cognitive impairment.

Explaining the change reduces dosing errors.

If someone is seizure-free

For a person whose seizure control is particularly fragile or for whom a breakthrough seizure would have major consequences, clinicians may decide that maintaining one preparation is preferable even when products are considered bioequivalent.

Never stop treatment because the brand changed

Missing antiseizure medicine entirely is usually more dangerous than receiving an approved alternative formulation during a shortage.

The central point

Approved generic antiseizure medicines are not “weaker copies”. Most switching is clinically safe, but the correct approach depends on the specific medicine, formulation, regulatory system and individual consequences of a breakthrough seizure.

Sources

Evidence checked: September 2026.